NDA 208711 · Novartis
Egaten
Triclabendazole · Oral · Anthelmintic
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Feb 13, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
44
24 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 4, 2026.
EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. EGATEN ® tablet is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.
Mechanism: Triclabendazole is an anthelmintic against Fasciola species [see Microbiology (12.4)] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- EGATEN · TRICLABENDAZOLE 250MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Triclabendazole" as an intervention, any sponsor and status, largest first.
- Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in SchoolchildrenPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01722539 · 616 participants · Start Nov 2012 · Primary completion Nov 2013
Drug: Sulfadoxine-pyrimethamine; Piperaquine and 2 more · For: Healthy
Sites: Kinshasa, Republic of the Congo
- One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic FascioliasisPivotal-lookingNot yet recruiting
Universidad Peruana Cayetano HerediaAcademic, hospital or other
NCT06367361 · 336 participants (planned) · Start Aug 15, 2026 · Primary completion Apr 15, 2029
Drug: Oxfendazole; Triclabendazole · For: Fascioliasis
Novartis PharmaceuticalsNovartis (NVS)
NCT04230148 · 301 participants · Start Feb 11, 2022 · Primary completion Mar 27, 2026
Drug: Egaten (Triclabendazole) 250 mg tablets · For: Fascioliasis
Sites: Medellín, Colombia; Cairo, Egypt; Alexandria, Egypt · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malaise7
- trematode infection5
- fascioliasis4
- condition aggravated3
- illness3
- nausea3
- overdose3
- rash3
- abdominal pain2
- chest pain2
- cough2
- diarrhoea2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 9 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 6 |
| 2025 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Triclabendazole in the treatment of human fascioliasis: a community-based study.
el-Morshedy H, Farghaly A, Sharaf S, et al. · East Mediterr Health J 1999 · Clinical Trial, Comparative Study
- Field trial on comparative efficacy of four fasciolicides against natural liver fluke infection in cattle.
Elitok B, Elitok OM, Kabu M · Vet Parasitol 2006 · Comparative Study, Randomized Controlled Trial
- Therapeutic effect of triclabendazole in patients with fascioliasis in Egypt. A preliminary study.
Hammouda NA, el-Mansoury ST, el-Azzouni MZ, et al. · J Egypt Soc Parasitol 1995 · Clinical Trial
- Efficacy of triclabendazole against Fasciola hepatica in the donkey (Equus asinus).
Trawford AF, Tremlett JG · Vet Rec 1996 · Clinical Trial, Controlled Clinical Trial
- Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina).
Olaechea F, Lovera V, Larroza M, et al. · Vet Parasitol 2011 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetic evaluation of different generic triclabendazole formulations in heifers.
Ortiz P, Castope N, Cabrera M, et al. · N Z Vet J 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.